These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 29025766)

  • 1. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.
    Min IM; Shevlin E; Vedvyas Y; Zaman M; Wyrwas B; Scognamiglio T; Moore MD; Wang W; Park S; Park S; Panjwani S; Gray KD; Tassler AB; Zarnegar R; Fahey TJ; Jin MM
    Clin Cancer Res; 2017 Dec; 23(24):7569-7583. PubMed ID: 29025766
    [No Abstract]   [Full Text] [Related]  

  • 2. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
    Gray KD; McCloskey JE; Vedvyas Y; Kalloo OR; Eshaky SE; Yang Y; Shevlin E; Zaman M; Ullmann TM; Liang H; Stefanova D; Christos PJ; Scognamiglio T; Tassler AB; Zarnegar R; Fahey TJ; Jin MM; Min IM
    Clin Cancer Res; 2020 Nov; 26(22):6003-6016. PubMed ID: 32887724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
    Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
    Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
    [No Abstract]   [Full Text] [Related]  

  • 4. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy.
    Vedvyas Y; McCloskey JE; Yang Y; Min IM; Fahey TJ; Zarnegar R; Hsu YS; Hsu JM; Van Besien K; Gaudet I; Law P; Kim NJ; Hofe EV; Jin MM
    Sci Rep; 2019 Jul; 9(1):10634. PubMed ID: 31337787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
    Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
    Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
    Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
    Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
    Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
    JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 9. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity.
    Park S; Shevlin E; Vedvyas Y; Zaman M; Park S; Hsu YS; Min IM; Jin MM
    Sci Rep; 2017 Oct; 7(1):14366. PubMed ID: 29085043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.
    Passaro C; Borriello F; Vastolo V; Di Somma S; Scamardella E; Gigantino V; Franco R; Marone G; Portella G
    Oncotarget; 2016 Jan; 7(2):1500-15. PubMed ID: 26625205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer.
    Zhou M; Chen Y; Adachi M; Wen X; Erwin B; Mawlawi O; Lai SY; Li C
    Biomaterials; 2015 Jul; 57():41-9. PubMed ID: 25913249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
    Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
    Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line.
    Hegedűs L; Rittler D; Garay T; Stockhammer P; Kovács I; Döme B; Theurer S; Hager T; Herold T; Kalbourtzis S; Bankfalvi A; Schmid KW; Führer D; Aigner C; Hegedűs B
    Pathol Oncol Res; 2020 Oct; 26(4):2523-2535. PubMed ID: 32591993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
    Raue F; Frank-Raue K
    Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is human leukocyte antigen-DR and intercellular adhesion molecule-1 expression on human thyrocytes constitutive in papillary thyroid cancer? Comparative studies in human thyroid xenografts in severe combined immunodeficient and nude mice.
    Kawai K; Resetkova E; Enomoto T; Fornasier V; Volpé R
    J Clin Endocrinol Metab; 1998 Jan; 83(1):157-64. PubMed ID: 9435434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
    Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
    Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.
    Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D
    Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway.
    Wang X; Zhang Y; Zheng J; Yao C; Lu X
    Cancer Immunol Immunother; 2021 Aug; 70(8):2235-2245. PubMed ID: 33486611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer.
    Antognelli C; Moretti S; Frosini R; Puxeddu E; Sidoni A; Talesa VN
    Cells; 2019 Jun; 8(6):. PubMed ID: 31174324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.